http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
View Older Stories
-
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
-
Trevi Therapeutics appoints David Hastings as chief financial officer
-
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
-
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
-
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
-
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
-
Trevi Therapeutics to present Phase 2a chronic cough trial data at ERS
-
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
-
Trevi Therapeutics to Participate in Upcoming September Conferences
-
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
-
Trevi Therapeutics to Participate in Upcoming August Conferences
-
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
-
Trevi Therapeutics (TRVI) Announces Positive Topline Results from the Phase 2b CORAL Trial
-
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
-
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
-
Trevi Therapeutics to Participate in Upcoming June Conferences
-
Trevi Therapeutics (TRVI) Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
-
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
-
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
-
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
-
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
-
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
-
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
-
Trevi Therapeutics (TRVI) Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio
-
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
-
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
-
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
-
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
-
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
-
Trevi Therapeutics (TRVI) Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
-
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
-
Trevi Therapeutics (TRVI) Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Pati
-
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients wi
-
Trevi Therapeutics (TRVI) Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
-
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
-
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
-
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
-
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
-
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
-
Trevi Therapeutics (TRVI) Provides Update on Haduvio's Clinical Development Program
-
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
-
Trevi Therapeutics (TRVI) Appoints James V. Cassella as Chief Development Officer
-
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
-
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
-
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
-
Trevi Therapeutics to Participate in September Investor and Medical Conferences
-
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
